Please login to the form below

Not currently logged in
Email:
Password:

Relvar

This page shows the latest Relvar news and features for those working in and with pharma, biotech and healthcare.

GSK wins US approval for Seretide successor Breo Ellipta

GSK wins US approval for Seretide successor Breo Ellipta

The combination is currently being considered by European regulatory authorities and if approved GSK plans to sell it as Relvar.

Latest news

  • Elan buys into GSK-partnered Theravance programmes for $1bn Elan buys into GSK-partnered Theravance programmes for $1bn

    Aside from Breo ( known as Relvar outside the US), Elan will get royalties on sales of COPD combination therapy Anoro ( umeclidinium bromide and vilanterol), vilanterol as a monotherapy and GSK961081, a

  • GSK replaces head of US operations GSK replaces head of US operations

    GSK needs its new generation of asthma and COPD therapies - including long-acting muscarinic antagonist ( LAMA) and long-acting beta agonist ( LABA) combination Anoro ( vilanterol and umeclidinium bromide) and Advair follow-up Relvar/Breo (

  • GSK trial throws everything at COPD GSK trial throws everything at COPD

    All three drugs will be delivering via GSK's Ellipta inhaler, which is already used in the company's recently introduced dual therapies Anoro ( umeclidinium and vilanterol) and Relvar/Breo ( fluticasone furoate and vilanterol).

  • SMC: Celgene's Abraxane 'too expensive' for Scotland SMC: Celgene's Abraxane 'too expensive' for Scotland

    SMC: Celgene's Abraxane 'too expensive' for Scotland. But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta. ... Drugs that received positive opinions included Janssen's Invokana ( canagliflozin) for type 2 diabetes, Jazz

  • GSK clear to launch COPD hope Anoro in Europe GSK clear to launch COPD hope Anoro in Europe

    Strengthens respiratory platform ahead of patent expiry for Advair/Seretide

More from news
Approximately 2 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ruder Finn UK Ltd

We are Ruder Finn A team of storytellers, digital makers and communicators In 2013 we grew by 20%. We recruited...

Latest intelligence

Russian innovation at the crossroads
Despite improvements, investors face rising risks...
blog-icon_webinar_wow_c.png
E-detailing content wow factor in 2015
Many companies are reporting that the iPad novelty has worn off and healthcare professionals are demanding more than just another animation presented on a mobile device. So what exactly are...
Free White Paper: Multichannel Marketing for Pharma
Transitioning successfully to multichannel marketing takes careful planning. When done right, pharma can deliver a personalised experience for each customer. Download our white paper to learn how...